OW Ghim Siong

EGF hijacks miR-198/FSTL1 wound-healing switch and steers a two-pronged pathway toward metastasis

Epithelial carcinomas are well known to activate a prolonged wound-healing program that promotes malignant transformation. Wound closure requires the activation of keratinocyte migration via a dual-state molecular switch. This switch involves production of either the anti-migratory microRNA miR-198 or the pro-migratory follistatin-like 1 (FSTL1) protein from a single transcript; miR-198 expression in healthy skin is down-regulated in favor of FSTL1 upon wounding, which enhances keratinocyte migration and promotes re-epithelialization.

type: 
Journal Paper
journal: 
The Journal of Experimental Medicine, 2017,doi: 10.1084/jem.20170354
Url: 
http://jem.rupress.org/content/early/2017/08/18/jem.20170354
Impact Factor: 
11.991
Date of acceptance: 
2017-07-12

Big genomics and clinical data analytics strategies for precision cancer prognosis

The field of personalized and precise medicine in the era of big data analytics is growing rapidly. Previously, we proposed our model of patient classification termed Prognostic Signature Vector Matching (PSVM) and identified a 37 variable signature comprising 36 let-7b associated prognostic significant mRNAs and the age risk factor that stratified large high-grade serous ovarian cancer patient cohorts into three survival-significant risk groups.

type: 
Journal Paper
journal: 
Scientific Reports 6, 2016, Article no. 36493 (2016), doi:10.1038/srep36493
pubmed: 
27819294
Url: 
https://www.ncbi.nlm.nih.gov/pubmed/27819294
Date of acceptance: 
2016-10-12

Big data and computational biology strategy for personalized prognosis

The era of big data and precision medicine has led to accumulation of massive datasets of gene expression data and clinical information of patients.

type: 
Journal Paper
journal: 
Oncotarget, 28 Jun 2016, Vol. 7, No. 26, Pg 40200-40220, doi: 10.18632/oncotarget.9571
pubmed: 
27229533
Url: 
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=9571&pubmed-linkout=1
Impact Factor: 
5.008
Date of acceptance: 
2016-05-01

Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development

Invasive ductal carcinoma (IDC) is a major histo-morphologic type of breast cancer. Histological grading (HG) of IDC is widely adopted by oncologists as a prognostic factor. However, HG evaluation is highly subjective with only 50%–85% inter-observer agreements. Specifically, the subjectivity in the assignment of the intermediate grade (histologic grade 2, HG2) breast cancers (comprising ~50% of IDC cases) results in uncertain disease outcome prediction and sub-optimal systemic therapy.

type: 
Journal Paper
journal: 
Oncotarget 2015, DOI: 10.18632/oncotarget.5543
Url: 
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5b%5d=5543
Impact Factor: 
6.359
Date of acceptance: 
2015-09-25

Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers

Background: The lack of consensus among reported gene signature subsets (GSSs) in multi-gene biomarker
discovery studies is often a concern for researchers and clinicians. Subsequently, it discourages larger scale prospective studies, prevents the translation of such knowledge into a practical clinical setting and ultimately hinders the progress of the field of biomarker-based disease classification, prognosis and prediction.

type: 
Journal Paper
journal: 
BMC Genomics 2015, 16(Suppl 7):S2 doi:10.1186/1471-2164-16-S7-S2
Url: 
http://www.biomedcentral.com/1471-2164/16/S7/S2
Impact Factor: 
3.99

Abstract 3815: CHEK2 mutation is an adverse prognostic survival factor for patients diagnosed with high-grade serous ovarian carcinoma

High-grade serous ovarian carcinoma (HG-SOC) is a poorly prognosed and lethal gynecological disease where only 30% of patients survive beyond five years after initial pathologic diagnosis. However, the heterogeneity of HG-SOC tumors meant that patients often respond differently despite similar clinical intervention.

type: 
Journal Paper
journal: 
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, Cancer Research Oct 1, 2015 74, 3815, doi: 10.1158/1538-7445.AM2014-3815
Url: 
http://cancerres.aacrjournals.org/content/74/19_Supplement/3815.short

Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures

High-grade serous ovarian cancer(HG-SOC), a major histologic type of epithelial ovarian cancer(EOC), is a poorly-characterized, heterogeneous and lethal disease where somatic mutations of TP53 are common and inherited loss-of-function mutations in BRCA1/2 predispose to cancer in 9.5–13% of EOC patients. However, the overall burden of disease due to either inherited or sporadic mutations is not known.

type: 
Journal Paper
journal: 
Cell Cycle, July 15 2014, Vol. 13, Issue 14, http://www.landesbioscience.com/journals/cc/toc/volume/13/issue/14/
Url: 
https://www.landesbioscience.com/journals/cc/article/29271/
Date of acceptance: 
2014-05-17

Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical sub-classes in high-grade serous ovarian carcinoma

High-grade serous ovarian carcinoma (HG-SOC) is a heterogeneous, poorly classified, lethal disease that frequently exhibits altered expressions of microRNAs. Let-7 family members are often reported as tumor suppressors; nonetheless, clinicopathological functions and prognostic values of individual let-7 family members have not been addressed in HG-SOC. In this work, we performed an integrative study to investigate the potential roles, clinicopathological functions and prognostic values of let-7 miRNA family in HG-SOC.

type: 
Journal Paper
journal: 
International Journal of Cancer 2013 Jul 3, doi: 10.1002/ijc.28371
pubmed: 
23825028
Url: 
http://www.ncbi.nlm.nih.gov/pubmed/23825028
Impact Factor: 
6.2
Date of acceptance: 
2013-06-18

How to discriminate between potentially novel and considered biomarkers within molecular signature?

The lack of consensus among reported molecular (gene, protein, regulatory marker) signatures (MSs) in the literature is often an initial concern for researchers and subsequently it discourages larger scale prospective studies,prevent the translation of such knowledge into a practical clinical setting and ultimately hindering the progress of the field of

type: 
Conference Paper/Poster
journal: 
2013 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (IEEE CIBCB 2013), April 15-19, Singapore

Targeting Glioma Stem Cells by Functional Inhibition of a Prosurvival OncomiR-138 in Malignant Gliomas

Malignant gliomas are the most aggressive forms of brain tumors, associated with high rates of morbidity and mortality. Recurrence and tumorigenesis are attributed to a subpopulation of tumor-initiating glioma stem cells (GSCs) that are intrinsically resistant to therapy. Initiation and progression of gliomas have been linked to alterations in microRNA expression. Here, we report the identification of microRNA-138 (miR-138) as a molecular signature of GSCs and demonstrate a vital role for miR-138 in promoting growth and survival of bona fide tumor-initiating cells with self-renewal potential.

type: 
Journal Paper
journal: 
Cell Reports 2012, doi:10.1016/j.celrep.2012.07.012
Url: 
http://www.cell.com/cell-reports/fulltext/S2211-1247%2812%2900222-7
Date of acceptance: 
2012-07-27
Syndicate content